Organisational Structure

Neuroallianz-Consortium strives to efficiently pursue its mission and objective and therefore has established an appropriate organisational structure using elements successfully established in industry:

The Project Teams are composed of a Project Leader, associated Project Leader and Project Team Members, who realise the project along predefined project plans. The Project Leader and the Project Team Members work in a collaborative, open and transparent manner.

The Steering Committee coordinates, steers, and leads the progress of the Neuroallianz project portfolio considering BMBF requirements and strategic recommendations of the Strategic Advisory Board.

A close and open collaboration between the partners will ensure successful processing of the Neuroallianz projects.

The Strategic Advisory Board is composed of members with outstanding experience in industrial enterprises and/or academic institutions.

The duty of the Strategic Advisory Boards - as strategic counsellor - is to give strategic and scientific recommendations on the research program.

The Consortium Manager is responsible for coordination and management of the Neuroallianz-Consortium and their representation in public.

The Scientific Coordinator of the University of Bonn supports the Consortium Manager in the coordination and management of all Neuroallianz activities at the University of Bonn.



To provide the German location of biotechnology and pharma industry with fresh impulsion, the German Federal Ministry for Education and Research (BMBF) started the pharma initiative "BioPharma: The Strategy Competition for Future Medicines". The Neuroallianz Consortium was nominated for this initiative.

The Neuroallianz Consortium has created a novel strategic partnership where various academic institutions and companies are working jointly on innovative diagnostic and therapeutic research projects. The aim is to efficiently transform research into benefits for the patients.

Main focuses are diagnostic and therapy of neurodegenerative diseases such as Parkinson's Disease, or Alzheimer's Dementia, and Epilepsy.

Duration: 2009 – 2018

Budget: 40 Mio. €